Literature DB >> 32154104

Rhodococcus hoagii bloodstream infection in an allogeneic hematopoietic stem cell transplantation patient: Case report and review of literature.

Pedro da Silva Campana1, Lorena Zaine Matos Martinho2, Marjorie Vieira Batista2, Hermes Higashino2, Camila Rizek3, Flavia Rossi4, Fernando Nivaldo Oliveira5, Vanderson Rocha6, Silvia Figueiredo Costa7.   

Abstract

We report a case of bloodstream infection caused by R. hoagii in a woman with acute myeloid leukemia, 37-years-old, who received an allogeneic hematopoietic stem cell transplant. She developed cutaneous and gastrointestinal tract graft versus host disease, respectively on day 29 and day 69. On day 157 she developed to acute severe respiratory failure. Rhodococcus sp was identified by MALDI-TOF and 16S rRNA sequencing from blood culture as Rhodococcus hoagii. The patient was a nurse that lived in urban areas, and stated no recent trips to countryside areas neither contacted with animals. Despite of the treatment with antibiotics with action against R. hoagii such as linezolid and meropenem the patient evolved to multiorgan dysfunction and death. Our case-report emphasizes the importance of early diagnosis and the use of 16S rRNA sequencing to confirmed the identification of species of Rhodococcus infection.
© 2020 The Authors.

Entities:  

Keywords:  Bacteremia; Hematopoietic stem cell transplantation; Rhodococcus hoagie

Year:  2020        PMID: 32154104      PMCID: PMC7057186          DOI: 10.1016/j.idcr.2020.e00724

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Introduction

Rhodococcus is a Gram-positive coccobacillus that belongs to the Actinomicetae order [1] This microorganism has been described as cause of infection in immunocompromised host such as Human Immunodeficiency Virus (HIV) and solid organ transplantation patients [1,2]. Moreover, few cases have been reported in hematopoietic stem cell transplantation (HSCT) patients, mostly in allogeneic (allo) patients with graft versus host diseases (GVHD) [3].

Case report

We present the case of a 37-year-old woman with acute myeloid leukemia (AML), colonized by vancomycin-resistant Enterococcus (VRE) who received an allo-HSCT from HLA compatible donor 5 months prior to admission. Bulsuphan, Fludarabine and Alemtuzumab were used as conditioning agents. The patient developed cutaneous and gastrointestinal tract GVHD, respectively on day 29 and 69. On day 69, she presented reactivation of cytomegalovirus (CMV) (RT-PCR CMV 6027 UI/mL, negativation within 3 weeks). On day 119, she was admitted to the hospital with dyspnea and cough, the baseline liver enzymes were normal (ALT 10 U/L and AST 15 U/L) and blood count (Hb = 7,0 gm/dL; Ht = 20,9%; leukocytes 940 cells/m3; neutrophils 790 cells/m3 and platelets 159,000). The chest computer tomography (CT) revealed opacities in the upper lobe of right lung and absence of halo sign, both galactomannan on bronchoalveolar lavage fluid and serum were positives (0.5 ODI and 0.73 ODI respectively) (Fig. 1). Thus, she started voriconazole (200 mg IV q 12 h), that was replaced later on by liposomal Amphotericin B (LAmB) 300 mg/d because of increased rates of liver enzymes (ALT 166 U/L and AST 85 U/L). Voriconazole was reintroduced (200 mg IV q12 h) when the liver enzymes were normal. There was improvement of pulmonary symptoms and radiological images with non-invasive ventilation after 23 days of antifungal drugs and GVHD treatment (metilprednisolone 90 mg/d) (Fig. 1). The patient was discharged from the hospital on day 142.
Fig. 1

Pulmonary CT before HSCT.

Pulmonary CT day 119 HSCT.

Pulmonary CT before HSCT. Pulmonary CT day 119 HSCT. On day 145, three days after she was discharged, the patient was hospitalized with dyspnea, acute kidney injury and CMV reactivation (RT-PCR CMV 401UI/mL) that was treated with ganciclovir (2,5 mg/kg/d IV q 12 h) adjusted for kidney function (KDIGO II). Blood cultures were collected, voriconazole was replaced by LAmB (3 mg/kg/d) and piperacilin-tazobactam (4,0 mg IV q6h) was introduced. On day 157 she evolved to acute severe respiratory failure and renal replacement therapy. She was transfer to the intensive care unit and mechanic ventilation was started. In this context, cultures were collected and trimethoprim/sulfamethoxazole (trimethoprim 15 mg/kg/d IV q6h), meropenem (1g IV q12h), colistin 2,5 mg/kg/d IV qDay), amikacin (15 mg/kg/d q24h) and linezolid (600 mg q12h) were given. Bronchoalveolar lavage was performed and Ziehl-Nielsen staining, bacteria and fungi cultures, Multiplex PCR for virus and galactomannan were negatives. Pulmonary CT before HSCT showed sparse and bilateral micronodules, measuring up to 0.3 cm and stable calcifications. Pulmonary CT on day 119 HSCT showed sparse nodules and micronodules, pneumonic foci in organization and opacity in frosted glass (Fig. 1). After five days, blood cultures were positive for Achromobacter sp. and Rhodococcus sp. using VITEK® Biomerieux-France and matrix-assisted laser desorption ionization with time of flight (MALDI-TOF-Biomerieux-France). We performed the sequencing of 16S ribosomal RNA gene (16S rRNA gene) of Rhodococcus sp to confirmed the identification that revealed 100 % of identity with Rhodococcus hoagii according to the National Center for Biotechnology Information (NCBI) database. Genebank access number SUB4217796 Seq1 MH539885. The central venous catheter was removed, moreover, despite the treatment with active antibiotics against R. hoagie as linezolid, amikacin and meropenem for 14 days, the patient evolved with multi organ dysfunction syndrome and death on day 172 (Fig. 2).
Fig. 2

Timeline showing main events that occurred during patient treatment.

Timeline showing main events that occurred during patient treatment.

Discussion

We present here a case report of a bloodstream infection (BSI) caused by R. hoagii in an allo-HSCT patient who evolved to death. This bacterium has been associated with severe infections such as BSI and pneumonia with high mortality in this population of patient; mainly allo-HSCT patients (Table 1).
Table 1

Cases of Rhodococcus in allo-HSCT patients described in the literature.

Year (Reference)Age yearsGenderRhodococcus speciesComorbiditiesClinical diagnosisTreatmentOutcome
1995 (10)29MaleR. equiLymphomaPneumniaNot reportedDeath
2008 (4)61MaleR. equiLymphomaPneumniaVancomycin (treatment failure); ertapenem and rifampicinCure
2012 (11)60MaleR. equiT-cell prolymphocytic LeukemiaLung nass, pleual malakoplakiaRight upperlobe lobectomyCure
2012 (5)64MaleR. corynebacteoidesMyelodysplastic syndromeBacteremiacefepime and cefozopranDeath
2012 (8)68MaleR. equiNot InformedMediastinitisVancomycin and ciprofloxacinNot repoted
2013 (7)61MaleR. globerulusAcute Myelomonocytic LeukemiaBacteremiaVancomycin and ciprofloxacinCure
2017 (present case)37FemaleR. equiAcute Myeloid LeukemiaPneumoniaMeropenem, amicakin and linezolidDeath
Cases of Rhodococcus in allo-HSCT patients described in the literature. Rhodococcus has been associated to exposure to rural areas. It transmission usually occurs by inhalation of contaminated soils; as the soils of horses ‘s farmers contains highly concentration of this bacteria [1,4,5]. Recently its taxonomy changed based on sequencing methods, thus, Rhodococcus equi was named as R. hoagii according to the rules of the Bacteriological Code [14]. Although the 16S rRNA gene sequencing analysis is an useful method to identify the Rhococcus; this gene is unable to differentiate some of Rhodococcus species [15,16]. Thus, this technique can result in misidentification of species. Up to now, whole genome sequencing (WGS) analysis is consider the trustworthy method to identify the species in this genus [[15], [16], [17]]. Moreover, the WGS is not available as routine in most of low income countries. In our case report the 16S rRNA sequencing revealed 100 % of identity with Rhodococcus hoagii according to NCBI database. The development of the infection by Rhodococcus occurred later than day 100 in most of cases of HSCT [4,[6], [7], [8], [9], [10], [11], [12], [13], [14], [15]]. Regarding risk factors; it has recently been shown, in a case-control study that 02 conditions (diabetes mellitus and a prior opportunistic infection) might increase the risk of infection caused by Rhodococcus [3]. Other authors, however, did not evidence any risk factors [4,[6], [7], [8], [9], [10], [11], [12], [13], [14], [15]]. In our report, the patient was a nurse that lived in urban areas, and stated no recent trips to countryside areas neither contact with animals. Infections caused by Rhodoccous are underreported and probably misdiagnosed because of a conjunction of factors that include the difficult of identification of genus and species by traditional techniques, and the importance of history as previous exposure to rural area, contact with animal as horse which should always prompt investigation. In addition, Rhodococcus is a diverse spectrum of disease [17]. Immunocompromised patients can present pneumonia, BSI, malakoplakia and mediastinitis caused by Rhodococcus [17]. This clinician characteristic makes the diagnostic hypothesis even more challenging. Most of the cases reported in transplantation patients described the lung as the mainly route of infection [4,[6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17]]. Around 80 % developed pulmonary cavity, and among immunocompromised populations, it is often observed disseminated disease as well [1]. Our patient presented respiratory symptoms but the respiratory cultures were negative. Although, she received a multidrug treatment including antibiotics with action against Rhococcus such as linezolid, amikacin and meropenem [13,14] she evolved to death. The literature recommends at least combination of two antibiotics such as vancomycin, carbapenems, aminoglycosides and quinolones, to treat infections caused by this microorganism [4,[6], [7], [8], [9], [10], [11], [12], [13], [14], [15]]. As for systemic infections, monotherapy might result in emergence of resistance [4,6,[7], [8], [9], [10], [11], [12], [13], [14], [15]]. But, there is no robust data to stablish the proper antibiotic regime to treat infections caused by this organism.

Conclusion

Our case-report emphasizes the importance of early diagnosis and the use of 16S rRNA sequencing as a tool to confirmed the identification of species of Rhodococcus infection.

Author contribution

PSC and L ZMM data collection analysis and writing; MV B; HH and FNO data collection; FR and CR laboratory and sequencing data; VR data collection and SFC data analysis and writing.

Funding

This study was supported by the laboratory funding.

Declaration of Competing Interest

All authors declare that they have no conflict of interest.
  14 in total

1.  Pleural malakoplakia caused by Rhodococcus equi infection in a patient after stem cell transplantation.

Authors:  Carl Ludwig Behnes; Silke Neumann; Stefan Schweyer; Heinz-Joachim Radzun
Journal:  Diagn Pathol       Date:  2012-02-23       Impact factor: 2.644

Review 2.  Rhodococcus globerulus bacteremia in an allogeneic hematopoietic stem cell transplant recipient: report of the first transplant case and review of the literature.

Authors:  P Ramanan; P J Deziel; R R Razonable
Journal:  Transpl Infect Dis       Date:  2014-05-02       Impact factor: 2.228

3.  First report of sepsis caused by Rhodococcus corynebacterioides in a patient with myelodysplastic syndrome.

Authors:  Yuka Kitamura; Etsuko Sawabe; Kiyofumi Ohkusu; Naoko Tojo; Shuji Tohda
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

4.  Rhodococcus equi: an emerging pathogen.

Authors:  David M Weinstock; Arthur E Brown
Journal:  Clin Infect Dis       Date:  2002-04-25       Impact factor: 9.079

5.  Clinical impact of the use of 16S rRNA sequencing method for the identification of "difficult-to-identify" bacteria in immunocompromised hosts.

Authors:  R Bharadwaj; S Swaminathan; H Salimnia; M Fairfax; A Frey; P H Chandrasekar
Journal:  Transpl Infect Dis       Date:  2011-10-28       Impact factor: 2.228

Review 6.  Rhodococcus equi infection.

Authors:  Alexandra V Yamshchikov; Audrey Schuetz; G Marshall Lyon
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 25.071

7.  Rhodococcus defluvii sp. nov., isolated from wastewater of a bioreactor and formal proposal to reclassify [Corynebacterium hoagii] and Rhodococcus equi as Rhodococcus hoagii comb. nov.

Authors:  P Kämpfer; W Dott; K Martin; S P Glaeser
Journal:  Int J Syst Evol Microbiol       Date:  2013-11-06       Impact factor: 2.747

8.  Primary retroperitoneal abscesses due to Rhodococcus equi in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline.

Authors:  Gianluca Russo; Miriam Lichtner; Martina Carnevalini; Maria Teresa Mascellino; Fabio Mengoni; Alessandra Oliva; Ginevra Azzurra Miccoli; Marco Iannetta; Vito Trinchieri; Anna Paola Massetti; Claudio Maria Mastroianni; Vincenzo Vullo
Journal:  Int J Infect Dis       Date:  2009-09-15       Impact factor: 3.623

9.  Rhodococcus equi--an increasingly recognized opportunistic pathogen. Report of 12 cases and review of 65 cases in the literature.

Authors:  M A Scott; B S Graham; R Verrall; R Dixon; W Schaffner; K T Tham
Journal:  Am J Clin Pathol       Date:  1995-05       Impact factor: 2.493

10.  Rhodococcus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients1.

Authors:  Pascalis Vergidis; Ella J Ariza-Heredia; Anoma Nellore; Camille N Kotton; Daniel R Kaul; Michele I Morris; Theodoros Kelesidis; Harshal Shah; Seo Young Park; M Hong Nguyen; Raymund R Razonable
Journal:  Emerg Infect Dis       Date:  2017-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.